AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 92 min read$MDT

Walter Matthew R. sold $258K of MDT

Walter Matthew R. (SVP, Chief HR Officer) sold 3,102 shares of Medtronic plc (MDT) at $83.15 ($0.26M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Walter Matthew R.
Published Jul 9, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

The disclosed sale is a concrete datapoint for insider activity, but it does not introduce new company-specific fundamentals (no guidance, trial, deal, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable for directional fundamental trades.

03

What to watch

The article does not state whether sales were part of a broader pattern, nor does it provide options activity or other holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 2/10Timing: new Form 4 filed July 9, covering a July 8 sale

Background

This is an SEC Form 4 insider transaction disclosure for Medtronic plc, reported as an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic insider Walter Matthew R., SVP Chief HR Officer, sold 3,102 shares for about $257,931 under a 10b5-1 plan on July 8.

Expected impact

Likely minimal impact on MDT price; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or financial catalyst.

Market effects

Sector

No clear read-across to medtech sector fundamentals from a single routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can reflect personal liquidity needs or risk management, which some traders may still fade.

Key entities

  • issuer
    Medtronic plc

    MDT, subject of the Form 4 insider transaction disclosure.

  • insider
    Walter Matthew R.

    SVP, Chief HR Officer who sold 3,102 shares on July 8 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDT insider trading history →

Related articles

SEP 17
$MDTHighAI 8/10

Medtronic Advances Diabetes Spin

Medtronic (MDT) launched an exchange offer for up to 225,361,295 MiniMed Group Inc. shares, part of its diabetes business separation. It corrected a prospectus error regarding the guaranteed delivery period for tender documentation, which now expires at 5:00 p.m. NY time on the second NYSE trading day after execution.

tipranks.com1 min
SEP 17
$MDTHighAI 9/10

[SC TO-I/A] Medtronic plc Amended Issuer Tender Offer

Medtronic plc amended its tender offer to exchange up to 225,361,295 shares of MiniMed Group, Inc. common stock for its own shares, with a potential increase of 27,452,053 shares if oversubscribed. The offer, filed with the SEC, aims to exchange approximately 80.1% of MiniMed's outstanding shares. MiniMed has also filed a registration statement for the new shares.

stocktitan.net2 min
SEP 17
$MDTMed

Medtronic plc (MDT): Other Events

Medtronic plc (MDT) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events On September 14, 2026, Medtronic plc, a public limited company organized under the laws of Ireland (“Medtronic”), commenced an offer to exchange (the “Exchange Offer”) up to 225,361,295 newly issued shares of common stock, par value $0.01 per share (“MiniM

SEC EDGAR 8-K2 min
SEP 17
$MDTHighAI 8/10

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic (MDT) shares are down 3% this year, but the company's Hugo robotic-assisted surgery system is gaining market share. The FDA approved Hugo for urological procedures, and Medtronic submitted new filings for broader use. Q1 2027 revenue was $9.8B, up 13.7% YoY, with EPS of $1.14, up 40.7%. The company raised full-year guidance and is on track to become a Dividend King. Medtronic's dividend yield is 3.06%, and it is expanding in cardiac and spinal technologies.

fool.com3 min
SEP 17
$MDTMed

Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth

Medtronic (MDT) reported Q1 growth of 7% (excluding an extra week), driven by innovations in cardiac ablation, renal denervation, robotics, and pelvic health. Cardiac ablation revenue surpassed $2B, while pelvic health revenue grew 15%. The company is investing in robotics, structural heart, and neuroscience, and plans to focus on tuck-in acquisitions. Medtronic expects to discuss its growth outlook further at an upcoming Investor Day.

yahoo.com3 min